

**NEULAND LABORATORIES LIMITED**

Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad - 34

**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2015**

**PART - I**

Amount in ₹ Lacs

Sl. No.	Particulars	Quarter Ended 30.06.2015 (Unaudited)	Quarter Ended 31.03.2015 (Unaudited)	Quarter Ended 30.06.2014 (Unaudited)	Year Ended 31.03.2015 (Audited)
1	<b>Income from Operations</b>				
	(a) Net Sales / Income from Operations	11,515.03	12,358.72	9,984.79	44,506.38
	(b) Other Operating Income	748.18	938.12	282.66	1,963.97
	<b>Total Income from Operations (Net)</b>	<b>12,263.21</b>	<b>13,296.84</b>	<b>10,267.45</b>	<b>46,470.35</b>
2	<b>Expenses</b>				
	(a) Consumption of Raw Materials	6,700.39	6,537.73	6,368.23	26,641.78
	(b) Changes in inventories of finished goods and work in process	(375.35)	677.81	(922.35)	(2,242.89)
	(c) Employee Benefit Expense	1,308.82	1,376.03	1,054.44	4,896.61
	(d) Depreciation	380.20	362.28	389.90	1,531.98
	(e) Manufacturing Expenses	1,444.13	1,265.74	1,241.51	5,563.22
	(f) Other Expenses	1,183.40	1,488.40	1,165.17	5,419.95
	<b>Total Expenses</b>	<b>10,641.59</b>	<b>11,707.99</b>	<b>9,296.90</b>	<b>41,810.65</b>
3	<b>Profit from Operations before Other Income, Finance Costs and Exceptional Items (1-2)</b>	<b>1,621.62</b>	<b>1,588.85</b>	<b>970.55</b>	<b>4,659.70</b>
4	Other Income	161.63	129.40	73.44	522.87
5	<b>Profit from Ordinary Activities before Finance Costs and Exceptional Items (3+4)</b>	<b>1,783.25</b>	<b>1,718.25</b>	<b>1,043.99</b>	<b>5,182.57</b>
6	Finance Costs	654.10	860.37	567.82	2,734.86
7	<b>Profit from Ordinary Activities after Finance Costs but before Exceptional Items (5-6)</b>	<b>1,129.15</b>	<b>857.88</b>	<b>476.17</b>	<b>2,447.71</b>
8	Exceptional Items	-	-	-	-
9	<b>Profit from Ordinary Activities before Tax (7-8)</b>	<b>1,129.15</b>	<b>857.88</b>	<b>476.17</b>	<b>2,447.71</b>
10	Tax Expense				
	(a) Current tax	475.68	302.87	103.90	671.38
	(b) Deferred Tax	(76.59)	(73.80)	173.83	198.20
	(c) MAT Credit entitlement	-	60.12	(103.90)	-
11	<b>Net Profit from Ordinary Activities after Tax (9-10)</b>	<b>730.06</b>	<b>568.69</b>	<b>302.34</b>	<b>1,578.13</b>
12	Extraordinary Items	-	-	-	-
13	<b>Net Profit for the period (11-12)</b>	<b>730.06</b>	<b>568.69</b>	<b>302.34</b>	<b>1,578.13</b>
14	Paid-up Equity Share Capital (Face Value ₹10 per share)	895.39	895.39	772.63	895.39
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				15,010.27
16	Earnings per Share (EPS) (in ₹)				
	(a) Basic	8.22	6.40	3.65	18.47
	(b) Diluted	8.22	6.40	3.65	18.47



**PART - II**

Sl. No.	Particulars	Quarter Ended 30.06.2015 (Unaudited)	Quarter Ended 31.03.2015 (Unaudited)	Quarter Ended 30.06.2014 (Unaudited)	Year Ended 31.03.2015 (Audited)
<b>A</b>	<b>PARTICULARS OF SHARE HOLDING</b>				
1	Public Shareholding				
	(a) Number of Shares	42,87,627	42,87,627	38,22,899	42,87,627
	(b) Percentage of Shareholding	48.27%	48.27%	49.94%	48.27%
2	Promoters and Promoter Group Shareholding				
	(a) Pledged / Encumbered				
	-Number of Shares	2,00,000	2,00,000	2,00,000	2,00,000
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	4.35%	4.35%	5.22%	4.35%
	-Percentage of Shares (as a % of the total share capital of the Company)	2.25%	2.25%	2.61%	2.25%
	(b) Non-encumbered				
	-Number of Shares	43,95,627	43,95,627	36,32,779	43,95,627
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	95.65%	95.65%	94.78%	95.65%
	-Percentage of Shares (as a % of the total share capital of the Company)	49.48%	49.48%	47.45%	49.48%

**B INVESTOR COMPLIANTS**

Particulars	Quarter Ended 30.06.2015
Pending at the beginning of the quarter	1
Received during the quarter	4
Disposed off during the quarter	5
Remaining unresolved at the end of the quarter	0

**NOTES:**

- The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on August 13, 2015, and approved and taken on record at the Board of Directors meeting held on August 14, 2015.
- EPS for the quarters are not annualized. EPS for the quarter ended June 30, 2014 has been recomputed to adjust for the bonus element of rights issue in accordance with the provisions of AS 20 - Earnings per Share.
- The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".
- Previous quarter / year numbers have been regrouped wherever necessary.

By Order of the Board  
For Neuland Laboratories Limited



Dr. D.R. Rao

Chairman & Managing Director  
(DIN 00107737)

Place: Hyderabad

Date: August 14, 2015